• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of cimetidine in patients undergoing hemodialysis.

作者信息

Bjaeldager P A, Jensen J B, Nielsen L P, Larsen N E, Hvidberg E F

出版信息

Nephron. 1983;34(3):159-63. doi: 10.1159/000183002.

DOI:10.1159/000183002
PMID:6877447
Abstract

In order to establish improved guidelines for dosage adjustments of cimetidine before and during hemodialysis, the kinetics of this drug was investigated in 7 uremic patients undergoing regular hemodialysis. The absorption fraction was found to be 0.75 (range 0.61-0.86), the terminal half-life in plasma between 138 and 238 min, the total body clearance (Cltotal) between 178 and 337 ml/min, and the apparent volume of distribution about 1 l/kg. During hemodialysis no excess amounts of cimetidine were removed from serum. In 3 patients a weak rebound phenomenon was seen after hemodialysis. Based on the Cltotal obtained in this study, dosage schemes producing a 24-hours mean steady state concentration from 0.60 (2.38) to 1.20 (4.76) mg/l (mumol/l) are suggested.

摘要

相似文献

1
Pharmacokinetics of cimetidine in patients undergoing hemodialysis.
Nephron. 1983;34(3):159-63. doi: 10.1159/000183002.
2
Elimination of oral cimetidine in chronic renal failure and during haemodialysis.慢性肾功能衰竭及血液透析期间口服西咪替丁的消除情况。
Br J Clin Pharmacol. 1980 Jun;9(6):585-92. doi: 10.1111/j.1365-2125.1980.tb01084.x.
3
Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion.通过腹膜透析、血液透析和活性炭血液灌流清除西咪替丁。
Ther Drug Monit. 1980;2(3):273-81. doi: 10.1097/00007691-198007000-00011.
4
Steady-state kinetics and dosage requirements of cimetidine in renal failure.
Clin Pharmacokinet. 1981 Jul-Aug;6(4):316-25. doi: 10.2165/00003088-198106040-00006.
5
The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.西咪替丁及其亚砜代谢产物在肾功能正常和受损患者中的药代动力学。
Br J Clin Pharmacol. 1982 Feb;13(2):163-70. doi: 10.1111/j.1365-2125.1982.tb01351.x.
6
Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.西咪替丁及其亚砜代谢物在血液透析期间的药代动力学。
Eur J Clin Pharmacol. 1982;21(4):325-30. doi: 10.1007/BF00637621.
7
Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.西咪替丁在肾功能正常和受损受试者中的生物利用度及药代动力学比较。
Clin Pharm. 1983 Mar-Apr;2(2):157-62.
8
Oral absorption of cimetidine and its clearance in patients with renal failure.
Eur J Clin Pharmacol. 1979 Apr 17;15(3):153-7. doi: 10.1007/BF00563098.
9
Rebound following hemodialysis of cimetidine and its metabolites.西咪替丁及其代谢产物血液透析后的反跳现象。
Am J Kidney Dis. 1984 May;3(6):430-5. doi: 10.1016/s0272-6386(84)80006-2.
10
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients.西咪替丁在胃溃疡和十二指肠溃疡患者中的药代动力学及生物利用度
Clin Pharmacokinet. 1980 Jan-Feb;5(1):84-94. doi: 10.2165/00003088-198005010-00003.

引用本文的文献

1
Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.肾功能不全患者中H2受体拮抗剂的药代动力学和药效学
Clin Pharmacokinet. 1993 Apr;24(4):319-32. doi: 10.2165/00003088-199324040-00005.
2
Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.肾衰竭患者消化性溃疡治疗的药代动力学优化
Clin Pharmacokinet. 1994 Nov;27(5):393-408. doi: 10.2165/00003088-199427050-00006.